CPT 80359 Methylenedioxyamphetamines Reimbursement

CPT code 80359 denotes a laboratory toxicology assay for the measurement or detection of methylenedioxyamphetamines in patient specimens. Drug-specific testing codes such as this are critical for clinical care, forensic evaluation, compliance monitoring, and public health surveillance. Nationally, accurate coding of targeted drug assays affects billing, utilization tracking, and program integrity across payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for methylenedioxyamphetamines testing, the typical laboratory and site-of-service settings for the procedure, and what to expect in payer coverage patterns. The publication summarizes common modifiers applicable to laboratory services and identifies where input data are not available.

This report provides concise benchmarks and policy-relevant notes for revenue teams and clinical laboratories: definitions of the service, typical use cases (clinical toxicology, emergency medicine, substance use monitoring), and practical considerations for submitting claims. Data not available in the input are explicitly flagged where relevant. The content is designed for national audiences involved in coding, billing, laboratory operations, and payer policy.

Billing Code Overview

CPT code 80359 describes a laboratory procedure in which a lab analyst measures the amount of, or detects the presence of, methylenedioxyamphetamines in a patient specimen. This service is a toxicology/drug testing assay focused on identifying methylenedioxy-substituted amphetamine compounds.

Service Type: Laboratory toxicology assay

Typical Site of Service: Clinical laboratory or hospital laboratory; specimens are commonly collected in outpatient clinics, emergency departments, or inpatient settings and sent to a certified laboratory for analysis.

Clinical Context

A typical patient scenario involves an adult who presents to an emergency department, urgent care, inpatient unit, or outpatient clinic with altered mental status, suspected recreational designer drug use, acute agitation, unexplained tachycardia or hypertension, or possible drug-facilitated assault. A clinician orders toxicology testing to detect methylenedioxyamphetamines (MDMA, MDA, MDEA) in a blood or urine specimen. The specimen is collected, labeled, and sent to the hospital clinical laboratory or a reference laboratory. A laboratory analyst performs an immunoassay screen or confirmatory analytical method (such as GC-MS or LC-MS/MS) specific for methylenedioxyamphetamines and documents the presence or quantitative amount. Results are reported back to the ordering clinician to inform acute management, disposition, forensic reporting, or occupational health decisions.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing for the interpretation/reporting component performed by a pathologist or laboratory physician separate from the technical testing.
`TC`	Technical component	Use when billing for the laboratory equipment, supplies, and technician work without the professional interpretation.

Taxonomy Code	Specialty	Notes
`207K00000X`	Clinical Pathology	Laboratory directors and clinical pathologists who oversee toxicology testing and interpretation.
`207L00000X`	Anatomic and Clinical Pathology	Pathologists who provide reporting and consultative services for confirmatory testing.
`193400000X`	Clinical Laboratory (General)	Medical technologists and laboratory managers responsible for performing the analytical assay.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F11.10`	Opioid abuse, uncomplicated	Co-testing for multiple substances is common in suspected substance use presentations where methylenedioxyamphetamines may be present.
`F14.10`	Cocaine abuse, uncomplicated	Differential toxicology panels often include stimulants and designer amphetamines.
`F15.10`	Other stimulant abuse, uncomplicated	Directly relevant for suspected amphetamine or methylenedioxyamphetamine exposure.
`R41.82`	Altered mental status, unspecified	Symptom prompting toxicology testing.
`T43.621A`	Poisoning by 3,4-methylenedioxyamphetamine (MDMA), accidental (unintentional), initial encounter	Specific poisoning code for methylenedioxyamphetamines used when confirmed exposure and documented encounter.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80307`	Drug test, presumptive, any number of drug classes, any number of devices or procedures, non-quantitative; multiple drug classes	Often used as an initial immunoassay screen for amphetamines including methylenedioxy derivatives prior to specific confirmatory testing.
`80305`	Drug test, presumptive, any number of drug classes, any number of devices or procedures, qualitative; 1-2 drug classes	May be used for point-of-care or limited presumptive testing when amphetamine class is one of the classes tested.
`80374`	Mass spectrometry, qualitative or quantitative, drug confirmation (eg, GC-MS, LC-MS/MS), per specimen	Commonly used for confirmatory testing to identify and quantify methylenedioxyamphetamines after a positive screen.
`86003`	Antibody, microorganism specific; quantitative or semi-quantitative, each	Not typically used for drugs of abuse; included only when immunoassay methods using antibodies are documented.
`99000`	Handling and/or conveyance of specimen	Not an official CPT code for this context; Data not available in the input.

OpenPayer

Summary & Overview

CPT 80359: Methylenedioxyamphetamines Measurement or Detection